Targeting the A3 adenosine receptor for glaucoma treatment (Review)

Fishman,Pnina; Cohen,Shira; Bar-Yehuda,Sara

doi:10.3892/mmr.2013.1413

Targeting the A3 adenosine receptor for glaucoma treatment (Review)

Authors:
- Pnina Fishman
- Shira Cohen
- Sara Bar-Yehuda
View Affiliations

Affiliations: Can-Fite BioPharma, Petach-Tikva 49170, Israel
Published online on: April 4, 2013 https://doi.org/10.3892/mmr.2013.1413
Pages: 1723-1725

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glaucoma is a worldwide disease and the second leading cause of blindness. Current treatments are associated with a number of side-effects and poor compliance, due to the requirement for treatment administration several times a day. These treatments typically aim to lower intraocular pressure (IOP); however, they are unable to protect retinal ganglion cells (RGCs) from undergoing apoptosis, which is the main cause of vision loss. A3 adenosine receptor (A3AR) agonists have been found to protect normal cells from undergoing apoptosis via the downregulation of death signals. Furthermore, A3AR agonists have been reported to have several ophthalmological effects, including the prevention of ganglion cell apoptosis in vitro and in vivo and anti‑inflammatory effects in experimental models of autoimmune uveitis. CF101, an orally bioavailable A3AR agonist, has been analyzed in dry eye syndrome phase II clinical trials and was identified to be safe and well tolerated. The anti‑inflammatory effect of CF101 was shown to significantly improve corneal staining, tear meniscus and tear break‑up time in dry eye patients. In addition, CF101 was found to decrease IOP in patients. The safety and efficacy of CF101, together with its suitability for oral administration, indicates that it has potential as a candidate drug for the treatment of glaucoma.

View Figures

View References

1	Varma R, Lee PP, Goldberg I and Kotak S: An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 152:515–522. 2011. View Article : Google Scholar : PubMed/NCBI
2	Fishman P, Bar-Yehuda S and Madi L: Adenosine, tumors and immunity. Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. Hasko G, Cronstein BN and Szabo C: Taylor and Francis; London: pp. 299–312. 2007
3	Chen GJ, Harvey BK, Shen H, et al: Activation of adenosine A₃ receptors reduces ischemic brain injury in rodents. J Neurosci Res. 84:1848–1855. 2006.
4	David M, Akerman L, Ziv M, et al: Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 26:361–367. 2012. View Article : Google Scholar : PubMed/NCBI
5	Avni I, Garzozi HJ, Barequet IS, et al: Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology. 117:1287–1293. 2010. View Article : Google Scholar : PubMed/NCBI
6	Silverman MH, Strand V, Markovits D, et al: Clinical evidence for utilization of the A₃ adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol. 35:41–48. 2008.PubMed/NCBI
7	Bagnis A, Papadia M, Scotto R and Traverso CE: Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs. 16:293–307. 2011. View Article : Google Scholar : PubMed/NCBI
8	Qu J, Wang D and Grosskreutz CL: Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res. 91:48–53. 2010. View Article : Google Scholar : PubMed/NCBI
9	Nakazawa T, Nakazawa C, Matsubara A, et al: Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci. 26:12633–12641. 2006. View Article : Google Scholar : PubMed/NCBI
10	Sivakumar V, Foulds WS, Luu CD, et al: Retinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retina. J Pathol. 224:245–260. 2011. View Article : Google Scholar : PubMed/NCBI
11	Baudouin C, Liang H, Hamard P, et al: The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 115:109–115. 2008. View Article : Google Scholar
12	Leske MC, Wu SY, Hennis A, et al; BESs Study Group. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 115:85–93. 2008. View Article : Google Scholar : PubMed/NCBI
13	The European Glaucoma Society. Treatment principles and options. Terminology and Guidelines for Glaucoma. Heijl A and Traverso CE: 3rd edition. Dogma SRL; Savona: pp. 117–131. 2008
14	Reardon G, Kotak S and Schwartz GF: Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 5:441–463. 2011. View Article : Google Scholar : PubMed/NCBI
15	Strahlman E, Tipping R and Vogel R: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 113:1009–1016. 1995.
16	Baudouin C, Hamard P, Liang H, et al: Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 111:2186–2192. 2004. View Article : Google Scholar : PubMed/NCBI
17	Pisella PJ, Debbasch C, Hamard P, et al: Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 45:1360–1368. 2004. View Article : Google Scholar : PubMed/NCBI
18	Rusk C, Sharpe E, Laurence J, et al: Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group. Clin Ther. 20:454–466. 1998.
19	Katz LJ: Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 11:119–126. 2002. View Article : Google Scholar : PubMed/NCBI
20	Feldman RM: Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 19:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
21	Cohen S, Stemmer SM, Zozulya G, et al: CF102 an A₃ adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 226:2438–2447. 2011.PubMed/NCBI
22	Fishman P, Bar-Yehuda S, Barer F, et al: The A₃ adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res. 269:230–236. 2001.
23	Matot I, Weiniger CF, Zeira E, et al: A₃ adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care. 10:R652006. View Article : Google Scholar
24	Xu Z, Jang Y, Mueller RA and Norfleet EA: IB-MECA and cardioprotection. Cardiovasc Drug Rev. 24:227–238. 2006. View Article : Google Scholar : PubMed/NCBI
25	Ge ZD, Peart JN, Kreckler LM, et al: Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A₃ adenosine receptor. J Pharmacol Exp Ther. 319:1200–1210. 2006.
26	Shneyvays V, Leshem D, Zinman T, et al: Role of adenosine A₁ and A₃ receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. Am J Physiol Heart Circ Physiol. 288:H2792–H2801. 2005.PubMed/NCBI
27	Zhang M, Hu H, Zhang X, et al: The A₃ adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. Neurochem Int. 56:35–41. 2010.
28	Zhang X, Zhang M, Laties AM and Mitchell CH: Balance of purines may determine life or death of retinal ganglion cells as A₃ adenosine receptors prevent loss following P2X7 receptor stimulation. J Neurochem. 98:566–575. 2006. View Article : Google Scholar : PubMed/NCBI
29	Schlötzer-Schrehardt U, Zenkel M, Decking U, et al: Selective upregulation of the A₃ adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci. 46:2023–2034. 2005.
30	Zhang M, Budak MT, Lu W, et al: Identification of the A₃ adenosine receptor in rat retinal ganglion cells. Mol Vis. 12:937–948. 2006.
31	Hu H, Lu W, Zhang M, et al: Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res. 91:425–432. 2010. View Article : Google Scholar
32	Bar-Yehuda S, Luger D, Ochaion A, et al: Inhibition of experimental auto-immune uveitis by the A₃ adenosine receptor agonist CF101. Int J Mol Med. 28:727–731. 2011.PubMed/NCBI
33	Avila MY, Stone RA and Civan MM: Knockout of A₃ adenosine receptors reduces mouse intraocular pressure. Invest Ophthalmol Vis Sci. 43:3021–3026. 2002.PubMed/NCBI
34	Jacobson KA, von Lubitz DK, Daly JW and Fredholm BB: Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci. 17:108–113. 1996. View Article : Google Scholar : PubMed/NCBI